Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer

Treatment with androgen-targeted therapies can induce upregulation of epithelial plasticity pathways. Epithelial plasticity is known to be important for metastatic dissemination and therapeutic resistance. The goal of this study is to elucidate the functional consequence of induced epithelial plasticity on AR regulation during disease progression to identify factors important for treatment-resistant and metastatic prostate cancer. We pinpoint the epithelial plasticity transcription factor, Snail, at the nexus of enzalutamide resistance and prostate cancer metastasis both in preclinical models of prostate cancer and in patients. In patients, Snail expression is associated with Gleason 9-10 high-risk disease and is strongly overexpressed in metastases as compared to localized prostate cancer. Snail expression is also elevated in enzalutamide-resistant prostate cancer cells compared to enzalutamide-sensitive cells, and downregulation of Snail re-sensitizes enzalutamide-resistant cells to enzalutamide. While activation of Snail increases migration and invasion, it is also capable of promoting enzalutamide resistance in enzalutamide-sensitive cells. This Snail-mediated enzalutamide resistance is a consequence of increased full-length AR and AR-V7 expression and nuclear localization. Downregulation of either full-length AR or AR-V7 re-sensitizes cells to enzalutamide in the presence of Snail, thus connecting Snail-induced enzalutamide resistance directly to AR biology. Finally, we demonstrate that Snail is capable of mediating-resistance through AR even in the absence of AR-V7. These findings imply that increased Snail expression during progression to metastatic disease may prime cells for resistance to AR-targeted therapies by promoting AR activity in prostate cancer.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-07-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/oncotarget.10476PMID 27409172PMCID 5226599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

  2016cited by this paper
• A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

  2016cited by this paper
• Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.

  2015cited by this paper
• Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer

  2015cited by this paper
• Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes

  2015cited by this paper
• The Molecular Taxonomy of Primary Prostate Cancer.

  2015cited by this paper
• The Evolutionary History of Lethal Metastatic Prostate Cancer

  2015cited by this paper
• Evaluation of an Epithelial Plasticity (EP) Biomarker Panel in Men with Localized Prostate Cancer

  2015cited by this paper
• Expression of androgen receptor splice variants in clinical breast cancers

  2015cited by this paper
• NF-κB gene signature predicts prostate cancer progression.

  2014cited by this paper
• Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014influential reference
• Mechanisms of the androgen receptor splicing in prostate cancer cells

  2014cited by this paper
• Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition.

  2014cited by this paper
• The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

  2014cited by this paper
• TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer

  2013cited by this paper
• AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.

  2013cited by this paper
• NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants

  2013cited by this paper
• Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

  2013cited by this paper
• AR Variant AR v567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer 1,2

  2013cited by this paper
• Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors*

  2013cited by this paper
• Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer Cells

  2013cited by this paper
• Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.

  2012cited by this paper
• Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

  2012cited by this paper
• Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

  2012cited by this paper
• Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

  2012cited by this paper
• Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases

  2011cited by this paper
• Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

  2011cited by this paper
• Molecular and Cellular Pathobiology Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression

  2011cited by this paper
• A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

  2011cited by this paper
• AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

  2011cited by this paper
• Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells

  2010cited by this paper
• Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

  2010cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells

  2010cited by this paper
• Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

  2010cited by this paper
• Role of androgens and the androgen receptor in epithelial‐mesenchymal transition and invasion of prostate cancer cells

  2010cited by this paper
• Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

  2009cited by this paper
• Snail1 is over‐expressed in prostate cancer

  2009cited by this paper
• Receptor activator of NF-κB ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells

  2009cited by this paper
• A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

  2009cited by this paper
• Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate

  2009cited by this paper
• Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells

  2009cited by this paper
• Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells

  2008cited by this paper
• Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3.

  2008influential reference
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

  2008cited by this paper
• Snail is a repressor of RKIP transcription in metastatic prostate cancer cells

  2008cited by this paper
• Activated Androgen Receptor Downregulates E-Cadherin Gene Expression and Promotes Tumor Metastasis

  2008cited by this paper
• Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchyme transition

  2007cited by this paper
• Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition.

  2006cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer.

  2003cited by this paper
• Cancer statistics

  1989cited by this paper

• Shared mechanisms for metastasis and drug resistance in prostate cancer.

  2025cites this paper
• Exploring the Role of Epithelial–Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review

  2025cites this paper
• Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment

  2025cites this paper
• Androgen receptor activation stabilizes a hybrid epithelial/mesenchymal phenotype in presence of Notch-Jagged signaling

  2025cites this paper
• Theoretical understanding of evolutionary dosing following tumor dynamics

  2024cites this paper
• High Mobility Group AT-hook 2: A Biomarker Associated with Resistance to Enzalutamide in Prostate Cancer Cells

  2024cites this paper
• Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis

  2023cites this paper
• Cocaine and amphetamine regulated transcript (CART): a newly characterized neuropeptide in human prostate

  2023cites this paper
• A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer

  2023influential citation
• Update on Epithelial-Mesenchymal Plasticity in Cancer Progression.

  2023cites this paper
• Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer.

  2023cites this paper
• Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective

  2023cites this paper
• Artepillin C overcomes apalutamide resistance through blocking androgen signaling in prostate cancer cells.

  2023cites this paper
• Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer

  2022influential citation
• A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer

  2022influential citation
• The Transcription Factors Zeb1 and Snail Induce Cell Malignancy and Cancer Stem Cell Phenotype in Prostate Cells, Increasing Androgen Synthesis Capacity and Therapy Resistance.

  2022cites this paper
• ISL1 Romotes Enzalutamide Resistance in Castration-resistant Prostate Cancer (CRPC) through Epithelial to Mesenchymal Transition (EMT)

  2021cites this paper
• Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance

  2021cites this paper
• The Hallmarks of Cancer as Ecologically Driven Phenotypes

  2021cites this paper
• Resistance to the Androgen Receptor Centred Therapies: Biology and Management

  2021cites this paper
• Resistance to second-generation androgen receptor antagonists in prostate cancer

  2021cites this paper
• ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)

  2021cites this paper
• Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

  2020cites this paper
• Investigation of the Correlation between Androgen Receptor and ZEB1 and its Value in Progression of Gastric Cancer

  2020cites this paper
• Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

  2020influential citation
• BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer

  2020cites this paper
• Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer

  2020cites this paper
• Phenotypic plasticity and lineage switching in prostate cancer

  2020cites this paper
• BRD4 regulates key transcription factors that drive epithelial–mesenchymal transition in castration-resistant prostate cancer

  2020cites this paper
• Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas

  2019cites this paper
• Molecular mechanisms of enzalutamide resistance in prostate cancer

  2019cites this paper
• Neural Transcription Factors in Disease Progression.

  2019cites this paper
• Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer

  2019cites this paper
• Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

  2018cites this paper
• Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1.

  2018cites this paper
• Exploration of the diagnostic value and molecular mechanism of miR-1 in prostate cancer: A study based on meta-analyses and bioinformatics

  2018cites this paper
• CD38 is methylated in prostate cancer and regulates extracellular NAD+

  2018cites this paper
• enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

  2018cites this paper
• Mechanisms of treatment induced cell plasticity in prostate cancer

  2018cites this paper
• PGC-1α régule un programme onco-métabolique capable de réprimer l’agressivité du cancer de la prostate

  2018cites this paper
• Molecular Targeted Therapies of Prostate Cancer

  2018cites this paper
• enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

  2018cites this paper
• ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.

  2018cites this paper
• A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome

  2018cites this paper
• Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

  2017cites this paper
• Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

  2017cites this paper
• The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression

  2017cites this paper
• Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer

  2017cites this paper
• Using circulating tumor cells to advance precision medicine in prostate cancer.

  2017cites this paper
• Sirtuin 7: a new marker of aggressiveness in prostate cancer

  2017cites this paper
• Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment

  2017cites this paper
• EMT and MET: necessary or permissive for metastasis?

  2017cites this paper
• TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis.

  2017cites this paper
• Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.

  2017cites this paper